Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2023.
-
Busy address KBO
102 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
GEO-PHARM from Ukkel, company number BE0667520049, closed financial year 2025 with a result of € 59,343 after tax. For that financial year GEO-PHARM recorded a gross margin of € 117,621 and equity of € 477,760. Compared with financial year 2024, the result moved from € 124,815 to € 59,343. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 477,760
▲ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 59,343
▼ 52% vs 2024
Profit after tax over the fiscal year.
€ 79,471
▲ 280% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 471,560.
People and assets in 2025
€ 7,434
▼ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3,396
Loans from banks and other lenders, long and short.
€ 3,165
▼ 82% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 14,703
▼ 63% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 124,808 | € 90,602 | € 200,683 | € 117,621 | ▼ 41% |
| Profit after taxes | € 87,495 | € 58,373 | € 124,815 | € 59,343 | ▼ 52% |
| Equity | € 235,228 | € 293,602 | € 418,417 | € 477,760 | ▲ 14% |
| Total debts | € 22,049 | € 83,187 | € 60,794 | € 21,264 | ▼ 65% |
| Cash | € 46,609 | € 41,179 | € 20,906 | € 79,471 | ▲ 280% |
| Retained profit | € 229,028 | € 287,402 | € 412,217 | € 471,560 | ▲ 14% |
| Bank debt | € 0 | € 0 | € 3,399 | € 3,396 | |
| Balance sheet total | € 257,277 | € 376,789 | € 479,212 | € 499,024 | ▲ 4% |
Key figures of GEO-PHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GEO-PHARM?
What happened at GEO-PHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 59,343 (▼ 52% vs 2024). filed late Source: NBB ↗
- Damien Thiéry became a director. NBB
- Brigitte Thewys became a director. NBB
- New establishment in Linkebeek. KBO
- New establishment in Ukkel. KBO
- Start of the company according to the CBE. KBO
In short
From € 87,495 profit in 2022 to € 59,343 profit in 2025.
Paid € 153,643 in corporate taxes since 2022.
Best year ever: 2024, with € 124,815 profit.
A new publication or filing at GEO-PHARM? We notify you, reason included.
Follow GEO-PHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind GEO-PHARM are Damien Thiéry and Brigitte Thewys.
Directors
According to the 2025 annual accounts
Damien Thiéry
Director
since 2022
Brigitte Thewys
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Kersbeeklaan 308
1180 Ukkel
Bloemhof 52
1630 Linkebeek
Active since 27 September 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 102 companies are registered at this address.
All companies at this address →qabirim
CASSART SPECIAL PRODUCTS
€ 2.2 million gross margin · 2025
TERRE & FEU
€ 41,948 gross margin · 2024
CPAPA
€ 3,417 gross margin · 2025
DG Consult-Horsinvest
€ -95,380 gross margin · 2025
+97 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0667.520.049
- VAT number
- BE 0667.520.049
- Registered office
- Kersbeeklaan 308, 1180 Ukkel
- Names & denominations
- GEO-PHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 December 2016
- Peppol
- Active · Active since 16 Dec 2025
- Activities · NACE
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten